Targeted therapy drugs transformed the outlook for people with the rare cancers known as gastrointestinal stromal tumors, enabling some to survive a decade or longer. A fraction of GIST patients, however, never respond to treatment. And most of those who do respond eventually relapse because cancer cells evolve and become resistant to the drugs designed to stop them. It’s the big limitation of targeted therapies. But researchers now have found a way to retarget GISTs that … Read More
Posts Tagged ‘targeted therapy’
Gordon Mills, M.D., Ph.D., the new director of precision oncology at Oregon Health & Science University, outlines his vision for the field Gordon Mills, M.D., Ph.D. (OHSU/Kristyna Wentz-Graff) The cancer diagnosis, a rare sarcoma, was devastating for an old friend of Gordon Mills. “We spent lots of time trying to understand his disease, trying to characterize it, and he went to my colleagues to ask about what was the next therapy for him,” Mills … Read More
Targeted cancer therapies work by singling out gene mutations that drive tumor growth, then using a drug to block the effects of the mutant gene. But tumors consist of millions of cells that may collectively harbor hundreds of different “driver” mutations. That means therapies for some cancers will have to target more than one mutation at a time to be successful. To help solve the problem, researchers at Oregon Health & Science University devised … Read More
Medicine had never seen anything like it before, Brian Druker, M.D., recalled. “These are people who’d been told to get their affairs in order. And now their blood counts are normal,” the director of the OHSU Knight Cancer Institute told Stat News reporter Bob Tedeschi. “But here’s the problem: When can you celebrate? I felt a little bit like walking on eggshells, because it’s like, OK, is this going to be a flash in the … Read More
Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A disease with a three- to five-year life expectancy became, for most patients, a chronic, long-term condition managed with a daily pill. And this week, researchers published the outcomes of people treated for more than 10 years with the drug imatinib (Gleevec), ushered from lab to clinical … Read More
The depth of remission achieved with the targeted therapy imatinib (Gleevec) raises a tough new question for some leukemia patients: is it ever safe to stop taking the breakthrough drug developed at OHSU?
Finding new treatment targets for aggressive prostate cancer, lymphoma and leukemia. Visualizing how breast tumors grow resistant to drug therapy. Using mobile phone sensors to track symptoms in patients with pancreatic cancer. These are some of the new pilot projects funded by the OHSU Knight Cancer Institute.
Gleevec binds to the kinase domain of the mutant enzyme BCR-ABL1 Life expectancy in patients with chronic myeloid leukemia has soared to a level almost equal to that of the general population, according to a Swedish study quantifying the life-saving impact of Gleevec, the targeted therapy ushered from lab bench to clinical success by Brian Druker, M.D., director of the OHSU Knight Cancer Institute.
Sadik Esener, Ph.D., the engineer tapped to lead a major new cancer early detection program at the OHSU Knight Cancer Institute. Medical science has come up with only a few ways to detect incipient cancers in healthy people. None of them can distinguish the aggressive, life-threatening cases from those that are unlikely to become lethal. Researchers have spent decades, for instance, trying to develop a screening test for ovarian cancer. Most women with this … Read More
Researchers have identified many of the altered genes and cell signaling pathways that drive papillary renal cell carcinoma, a poorly understood form of cancer that accounts for about 15 percent of kidney tumors. The findings, published today in the New England Journal of Medicine, are likely to affect clinical recommendations, and should help guide the development of more precisely targeted therapies. No effective treatment exists for advanced papillary renal cell carcinoma.